瑞德西韦导致的心动过缓。
Remdesivir-Induced Bradycardia.
机构信息
From Osmania Medical College, Hyderabad, India.
Tianjin Medical University, Tianjin, P.R. China.
出版信息
South Med J. 2023 Mar;116(3):317-320. doi: 10.14423/SMJ.0000000000001519.
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved to improve recovery time; however, remdesivir also can induce significant cytotoxic effects on cardiac myocytes. In this narrative review, we discuss the pathophysiological mechanism of remdesivir-induced bradycardia and diagnostic and management strategies for these patients. We conclude that further research is necessary to understand better the mechanism of bradycardia in coronavirus disease 2019 patients with or without cardiovascular disorder treated with remdesivir.
瑞德西韦是一种病毒 RNA 依赖性 RNA 聚合酶抑制剂，在 2019 年冠状病毒病感染患者中广泛应用，因为它可以抑制病毒载量的扩增。在因下呼吸道感染而住院的患者中，瑞德西韦被证明可以缩短康复时间；然而，瑞德西韦也会对心肌细胞产生显著的细胞毒性作用。在这篇叙述性综述中，我们讨论了瑞德西韦引起心动过缓的病理生理机制，以及这些患者的诊断和管理策略。我们的结论是，需要进一步的研究来更好地理解瑞德西韦治疗的伴有或不伴有心血管疾病的 2019 年冠状病毒病患者心动过缓的机制。
Zotero 插件